Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer's disease

American Journal of Pathology

Volumn 178, Issue 5, 2011, Pages 2286-2298

  Lord, Anna ^a,c   Philipson, Ola ^a   Klingstedt, Therése ^d   Westermark, Gunilla ^b   Hammarström, Per ^d   Nilsson, K Peter R ^d   Nilsson, Lars N G ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c BioArctic Neuroscience   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HETEROZYGOTE; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE;

EID: 79959205998     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.01.052     Document Type: Article

References (59)

1. Hardy J: A hundred years of Alzheimer's disease research. Neuron 2006, 52:3-13
2. Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Näslund J, Axelman K, Bird TD, Nochlin D, Schellenberg GD, Wahlund LO, Lannfelt L: Clinical and neuropathological features of the Arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol 2008, 65:499-505 (Pubitemid 351549959)
3. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Näslund J, Lannfelt L: The "Arctic" APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001, 4:887-893
4. Johansson AS, Berglind-Dehlin F, Karlsson G, Edwards K, Gellerfors P, Lannfelt L: Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt. FEBS J 2006, 273:2618-2630
5. Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN: The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging 2006, 27:67-77 (Pubitemid 41627951)
6. Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, Nilsson LN: Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 2005, 58:147-150 (Pubitemid 40962471)
7. Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE: Sensitive ELISA detection of amyloidbeta protofibrils in biological samples. J Neurochem 2007, 103: 334-345 (Pubitemid 47404222)
8. Sahlin C, Lord A, Magnusson K, Englund H, Almeida CG, Greengard P, Nyberg F, Gouras GK, Lannfelt L, Nilsson LN: The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. J Neurochem 2007, 101:854-862 (Pubitemid 46646626)
9. Lord A, Englund H, Söderberg L, Tucker S, Clausen F, Hillered L, Gordon M, Morgan D, Lannfelt L, Pettersson FE, Nilsson LN: Amyloidbeta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J 2009, 276:995-1006
10. Philipson O, HammarströM P, Nilsson KP, Portelius E, Olofsson T, Ingelsson M, Hyman BT, Blennow K, Lannfelt L, Kalimo H, Nilsson LN: A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. Neurobiol Aging 2009, 30:1393-1405
11. Jarrett JT, Lansbury PT Jr: Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993, 73:1055-1058
12. Gajdusek DC: Transmissible and nontransmissible dementias: distinction between primary cause and pathogenetic mechanisms in Alzheimer's disease and aging. Mt Sinai J Med 1988, 55:3-5
13. Cheng IH, Palop JJ, Esposito LA, Bien-Ly N, Yan F, Mucke L: Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med 2004, 10:1190-1192 (Pubitemid 39540434)
14. Prusiner SB: Molecular biology of prion diseases. Science 1991, 252:1515-1522
15. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD: Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283: 1571-1577 (Pubitemid 30161512)
16. Åslund A, Sigurdson CJ, Klingstedt T, Grathwohl S, Bolmont T, Dickstein DL, Glimsdal E, Prokop S, Lindgren M, Konradsson P, Holtzman DM, Hof PR, Heppner FL, Gandy S, Jucker M, Aguzzi A, Hammarström P, Nilsson KP: Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. ACS Chem Biol 2009, 4:673-684
17. Nilsson LN, Bales KR, DiCarlo G, Gordon MN, Morgan D, Paul SM, Potter H: Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J Neurosci 2001, 21:1444-1451 (Pubitemid 32182186)
18. Wiltfang J, Arold N, Neuhoff V: A new multiphasic buffer system for sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins and peptides with molecular masses 100,000-1000, and their detection with picomolar sensitivity. Electrophoresis 1991, 12:352-366
19. Klafki HW, Wiltfang J, Staufenbiel M: Electrophoretic separation of betaA4 peptides (1-40) and (1-42). Anal Biochem 1996, 237:24-29 (Pubitemid 26155625)
20. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB: Amyloid beta-protein fibrillogenesis: detection of a protofibrillar intermediate. J Biol Chem 1997, 272:22364-22372 (Pubitemid 27382873)
21. LeVine H III: Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 1993, 2:404-410
22. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L: High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000, 20:4050-4058 (Pubitemid 30365675)
23. Sigurdson CJ, Nilsson KP, Hornemann S, Manco G, Polymenidou M, Schwarz P, Leclerc M, HammarströM P, Wuthrich K, Aguzzi A: Prion strain discrimination using luminescent conjugated polymers. Nat Methods 2007, 4:1023-1030 (Pubitemid 350201774)
24. Nilsson KP, Åslund A, Berg I, Nystrom S, Konradsson P, Herland A, Inganäs O, Stabo-Eeg F, Lindgren M, Westermark GT, Lannfelt L, Nilsson LN, HammarströM P: Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes. ACS Chem Biol 2007, 2:553-560
25. Berg I, Nilsson KP, Thor S, Hammarström P: Efficient imaging of amyloid deposits in Drosophila models of human amyloidoses. Nat Protoc 2010, 5:935-944
26. Nilsson LN, Arendash GW, Leighty RE, Costa DA, Low MA, Garcia MF, Cracciolo JR, Rojiani A, Wu X, Bales KR, Paul SM, Potter H: Cognitive impairment in PDAPP mice depends on ApoE and ACTcatalyzed amyloid formation. Neurobiol Aging 2004, 25:1153-1167 (Pubitemid 39094018)
27. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM: Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997, 17:263-264
28. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, Kisilevsky R, Lindahl U: In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis, Proc Natl Acad Sci USA 2005, 102:6473-6477
29. DeMattos RB, O'Dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM: Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease, Proc Natl Acad Sci USA 2002, 99: 10843-10848
30. Scheuermann S, Hambsch B, Hesse L, Stumm J, Schmidt C, Beher D, Bayer TA, Beyreuther K, Multhaup G: Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease. J Biol Chem 2001, 276:33923-33929
31. Rönnbäck A, Zhu S, Dillner K, Aoki M, Lilius L, Näslund J, Winblad B, Graff C: Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model. Neurobiol Aging 2011, 32:280-292
32. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GT, Luyendijk W, Frangione B: Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990, 248:1124-1126
33. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Sturchler-Pierrat C, Burki K, van Duinen SG, Maat-Schieman ML, Staufenbiel M, Mathews PM, Jucker M: Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004, 7:954-960
34. Herzig MC, Eisele YS, Staufenbiel M, Jucker M: E22Q-mutant Abeta peptide (AbetaDutch) increases vascular but reduces parenchymal Abeta deposition. Am J Pathol 2009, 174:722-726
35. Mori H, Takio K, Ogawara M, Selkoe DJ: Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 1992, 267:17082-17086
36. Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, Lopez J, Brune D, Sisodia SS, Staufenbiel M, Emmerling M, Roher AE: APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 2002, 41:922-928 (Pubitemid 34061994)
37. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M: Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA 1999, 96:14088-14093
38. Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, Younkin SG, Borchelt DR: Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem 2007, 282:22707-22720 (Pubitemid 47267316)
39. Armstrong RA: Beta-amyloid plaques: stages in life history or independent origin? Dement Geriatr Cogn Disord 1998, 9:227-238
40. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L: Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 1997, 94:1550-1555
41. Gibson PH: Relationship between numbers of cortical argentophilic and congophilic senile plaques in the brains of elderly people with and without senile dementia of Alzheimer type. Gerontology 1985, 31:321-324
42. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ: Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996, 3:16-32
43. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y: Amyloid beta protein (A beta) deposition: a beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol 1995, 37:294-299
44. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT: Rapid appearance and local toxicity of amyloid- beta plaques in a mouse model of Alzheimer's disease. Nature 2008, 451:720-724 (Pubitemid 351220570)
45. Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM: Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci 2009, 29:10706-10714
46. Philipson O, Lannfelt L, Nilsson LN: Genetic and pharmacological evidence of intraneuronal Abeta accumulation in APP transgenic mice. FEBS Lett 2009, 583:3021-3026
47. Prusiner SB: Prions. Proc Natl Acad Sci USA 1998, 95:13363-13383
48. Lazarov O, Lee M, Peterson DA, Sisodia SS: Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 2002, 22:9785-9793 (Pubitemid 35332862)
49. Sheng JG, Price DL, Koliatsos VE: Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J Neurosci 2002, 22:9794-9799 (Pubitemid 35332863)
50. Wisniewski T, Frangione B: Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992, 135:235-238
51. Potter H, Wefes IM, Nilsson LN: The inflammation-induced pathological chaperones ACT and Apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol Aging 2001, 22:923-930 (Pubitemid 34066560)
52. Söderberg L, Bogdanovic N, Axelsson B, Winblad B, Naslund J, Tjernberg LO: Analysis of single Alzheimer solid plaque cores by laser capture microscopy and nanoelectrospray/tandem mass spectrometry. Biochemistry 2006, 45:9849-9856 (Pubitemid 44257430)
53. O'Callaghan P, Sandwall E, Li JP, Yu H, Ravid R, Guan ZZ, van Kuppevelt TH, Nilsson LN, Ingelsson M, Hyman BT, Kalimo H, Lindahl U, Lannfelt L, Zhang X: Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells. Brain Pathol 2008, 18:548-561
54. Watson DJ, Lander AD, Selkoe DJ: Heparin-binding properties of the amyloidogenic peptides Abeta and amylin: dependence on aggregation state and inhibition by Congo red. J Biol Chem 1997, 272:31617-31624 (Pubitemid 28013306)
55. LeVine H III: Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 1999, 309:274-284
56. Hasegawa K, Yamaguchi I, Omata S, Gejyo F, Naiki H: Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 1999, 38:15514-15521
57. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E: Abeta40 inhibits amyloid deposition in vivo. J Neurosci 2007, 27:627-633 (Pubitemid 46143766)
58. O'Nuallain B, Williams AD, Westermark P, Wetzel R: Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 2004, 279:17490-17499 (Pubitemid 38560512)
59. Lashuel HA, Hartley DM, Petre BM, Wall JS, Simon MN, Walz T, Lansbury PT Jr: Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 2003, 332:795-808 (Pubitemid 37101368)